IDSA Reverses on Actemra; 500K COVID Deaths; J&J Says 20M Vax Doses by Spring



(MedPage Today) — Note that some links may require registration or subscription.
The Infectious Diseases Society of America (IDSA) changed course on tocilizumab (Actemra), and now conditionally recommends the IL-6 blocker on top of standard care…

Source link

Comments are closed, but trackbacks and pingbacks are open.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy